The invention belongs to the field of chemical analysis and detection, and specifically relates to a pretreatment method for LC-MS detecting metabolomics of Aspergillus flavus. The method includes: culturing a strain of Aspergillus flavus; quenching the Aspergillus flavus; disrupting the cell membrane of Aspergillus flavus, and extracting a metabolome. The invention adopts a cold glycerol buffer solution combined with a rapid filtration method for quenching, and a MeOH/DCM/ACN/EA/HCOOH mixture is used as an metabolome extract, thereby achieving the object of efficiently extracting different polar compounds, and metabolome compound coverage is high; pretreatment of the cell metabolomics of Aspergillus flavus by the method of the invention can ensure the repeatability and stability of the metabolomics analysis method and reduce the false positive of the test results.

The invention relates to antibodies to Aspergillus species and to methods of producing those antibodies. The invention also relates to the use of such antibodies in identifying the presence of the Aspergillus species and to methods of treating an infection with the Aspergillus species.

The present invention provides a hybridoma cell under the accession number CGMCC No. 13827. The hybridoma cell is capable of producing a monoclonal antibody against Aspergillus galactomannan antigen and a kit is prepared using the same. The kit provided by the present invention can specifically bind to the GM antigen, has both sensitivity and specificity of more than 95%, a detection limit of 0.85 ng/mL compared to 1 ng/mL of the existing product, and high compliance rate between the detection result and the reference reagent, and can provide more accurate and reliable detection results, so that IA can be detected early in the course of the disease and the patients can receive treatment in timely and effective manner, thereby improving the survival rate of patients. Moreover, the kit has simple and convenient operation, rapid and sensitive detection, which provides an effective tool for the quantitative detection of Aspergillus GM antigen.

Methods for diagnosing, treating, and monitoring the treatment of invasive aspergillosis (IA) are described. The methods can include detecting the presence of one or more volatile organic compounds (VOCs) in the breath of subjects suspected of having IA.

An Aspergillus infection is diagnosed in a patient by detecting in a sample a proteinaceous antigen derived from mycelium of a pathogenic Aspergillus strain, wherein the sample is contacted with a first antibody binding specifically to said antigen and wherein any antigen bound to said first antibody is detected by way of a non-membrane based immunoassay, preferably selected from an ELISA and a bead-based assay. An antibody binding to a proteinaceous antigen derived from mycelium of a pathogenic Aspergillus strain is used for increasing the reliability of an immunoassay or the diagnosis of an Aspergillus infection in a patient. A further method includes coating a diagnostic device with a first antibody binding specifically to a proteinaceous antigen derived from mycelium of a pathogenic Aspergillus strain.

Disclosed is a composition for extracting mycotoxins or aflatoxins from a food sample. The methods using the composition to detect and analyze the aflatoxins are also provided.

Methods for diagnosing, treating, and monitoring the treatment of invasive aspergillosis (IA) are described. The methods can include detecting the presence of one or more volatile organic compounds (VOCs) in the breath of subjects suspected of having IA.

The present invention provides a hybridoma cell under the accession number CGMCC No. 13827. The hybridoma cell is capable of producing a monoclonal antibody against Aspergillus galactomannan antigen and a kit is prepared using the same. The kit provided by the present invention can specifically bind to the GM antigen, has both sensitivity and specificity of more than 95%, a detection limit of 0.85 ng/mL compared to 1 ng/mL of the existing product, and high compliance rate between the detection result and the reference reagent, and can provide more accurate and reliable detection results, so that IA can be detected early in the course of the disease and the patients can receive treatment in timely and effective manner, thereby improving the survival rate of patients. Moreover, the kit has simple and convenient operation, rapid and sensitive detection, which provides an effective tool for the quantitative detection of Aspergillus GM antigen.

Methods for diagnosing, treating, and monitoring the treatment of invasive aspergillosis (IA) are described. The methods can include detecting the presence of one or more volatile organic compounds (VOCs) in the breath of subjects suspected of having IA.

A method of detecting a heat-resistant fungus, which has a step of identifying the heat-resistant fungus using the following nucleic acid (I) or (II): (I) a nucleic acid including a nucleotide sequence set forth in any one of SEQ ID NOS: 24 to 35 and 83 to 86, or a complementary sequence thereof; or (II) a nucleic acid including a nucleotide sequence resulting from a deletion, substitution, or addition of one to several nucleotides in the nucleotide sequence set forth in any one of SEQ ID NOS: 24 to 35 and 83 to 86 and being capable of detecting the heat-resistant fungus, or a complementary sequence thereof.